Related Experiment Video
Updated: Mar 12, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.2K
Insulin: Making Sense of Current Options
Alissa R Segal1, Tejaswi Vootla2, Richard S Beaser2
1Department of Pharmacy Practice, MCPHS University, 179 Longwood Avenue, Boston, MA 02115, USA; Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA.
Endocrinology and Metabolism Clinics of North America
|November 9, 2016
Summary
New insulin therapies, including modified formulations and advanced delivery devices, offer improved glucose control and safety. Personalized treatment decisions are key for optimizing insulin replacement in diabetes management.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Insulin replacement therapy is central to diabetes management.
- Traditional insulin formulations have limitations in mimicking physiological insulin secretion.
Purpose of the Study:
- To review advancements in insulin products and administration.
- To highlight how new tools can improve insulin replacement therapy.
Main Methods:
- Review of novel insulin products, including modified, concentrated, and inhaled insulins.
- Examination of advanced insulin delivery devices.
- Analysis of new insulin combination therapies.
Main Results:
- New insulin products offer more precise mimicry of natural insulin action.
- Advanced devices enhance adherence and safety.
- Combination therapies integrate basal and rapid-acting insulins or GLP-1 receptor agonists.
Conclusions:
- Modern insulin options and devices can significantly improve efficacy and safety.
- Individualized patient factors are crucial for selecting appropriate insulin therapies.
Related Concept Videos
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.8K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.8K
01:27Insulin Formulations: Types and Delivery
930
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
930
01:16Insulin: Dosing Regimen and Adverse Effects
1.0K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.0K
01:28Insulin: The Receptor and Signaling Pathways
5.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
5.5K
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.9K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.9K